Abstract
EPH193 The Role of Adjuvant Atezolizumab in Reducing Recurrence-Related Treatment Costs in Resected Early-Stage PD-L1 High Non-Small Cell Lung Cancer across Europe
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have